Table 2.
Summary of prior chemotherapy regimens
| Treatment group | Number of enrolled patients | Median cycles (range) | Median RDI (range) |
|---|---|---|---|
| First line | 38 | 7.5 (2–14) | 0.97 (0.76–1) |
| (Oral) 5-FU + cisplatin | 12 | 6 (3–12) | 1.0 (0.76–1) |
| Taxanes + 5-FU | 9 | 8 (2–12) | 1.0 (0.81–1) |
| Taxanes + cisplatin | 9 | 8 (3–11) | 0.96 (0.89–1) |
| (Oral) 5-FU + oxaliplatin | 6 | 8.5 (6–14) | 1.0 (0.89–1) |
| Othersa | 2 | NA | NA |
| Second line | 20 | 4 (2–14) | 0.95 (0.64–1) |
| Taxanes + 5-FU | 10 | 2 (1–9) | 0.93 (0.64–1) |
| (Oral) 5-FU + oxaliplatin | 5 | 9 (2–14) | 0.95 (0.76–1) |
| Othersb | 5 | NA | NA |
| Third line | 7 | 4 (2–6) | 0.86 (0.63–1) |
| (Oral) 5-FU + oxaliplatin | 4 | 3.5 (2–6) | 0.82 (0.63–1) |
| Taxanes | 3 | 4 (4–6) | 0.86 (0.73–1) |
NA not assessable, RDI relative dose intensity, 5-FU 5-fluorouracil
aPemetrexed + cisplatin; capecitabine + doccetaxel
b5-FU + adriamycin (n = 2), 5-FU + cisplatin, capecitabine + cisplatin, vinflunine